No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ZURA Zura Bio
- 4.710
- +0.070+1.51%
Close May 8 16:00 ET
- 4.898
- +0.188+4.00%
Pre 08:21 ET
293.56MMarket Cap-2965P/E (TTM)
4.880High4.560Low93.88KVolume4.560Open4.640Pre Close445.34KTurnover0.52%Turnover RatioLossP/E (Static)62.33MShares13.00052wk High4.95P/B84.94MFloat Cap2.00052wk Low--Dividend TTM18.03MShs Float37.550Historical High--Div YieldTTM6.90%Amplitude2.000Historical Low4.743Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
10-Q: Quarterly report
Zura Bio 1Q Loss/Shr 2c >ZURA
Zura Bio 1Q Loss/Shr 2c >ZURA
Zura Bio 1Q Loss $7.75M >ZURA
Zura Bio 1Q Loss $7.75M >ZURA
Express News | Zura Bio Ltd: Projected Cash Runway Extends Support for Operations Through 2027
Express News | Zura Bio Ltd: On Track to Initiate Phase 2 Studies Evaluating Tibulizumab (Zb-106) for Treatment of Systemic Sclerosis (Ssc) in Q4 2024
Express News | Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
Comments
Zura Bio Garners Enthusiastic Ratings from Analysts with a Bright Outlook.
Zura Bio (NASDAQ:ZURA), Piper Sandler, a prestigious investment firm, has initiated coverage on the biotechnology company, assigning it an "overweight" rating and setting an ambitious price target of $26. This optimistic forecast suggests a potential upside of 462.77% from the stock's previous close. The announcement by Piper Sandler und...
Zura Bio (NASDAQ:ZURA), Piper Sandler, a prestigious investment firm, has initiated coverage on the biotechnology company, assigning it an "overweight" rating and setting an ambitious price target of $26. This optimistic forecast suggests a potential upside of 462.77% from the stock's previous close. The announcement by Piper Sandler und...
1
$Zura Bio(ZURA.US$ SC 13G: Statement of acquisition of beneficial ownership by individuals-Venrock Healthcare Capital Partners III, L.P.(9.99%),VHCP Co-Investment Holdings III, LLC(9.99%), etc.
SC 13G: Statement of acquisition of beneficial ownership by individuals-RA Capital Management, L.P.(5.1%),Peter Kolchinsky(5.1%), etc.
SC 13G: Statement of acquisition of beneficial ownership by individuals-RA Capital Management, L.P.(5.1%),Peter Kolchinsky(5.1%), etc.
1
1
1
$Two (TWOA.US)$ Good morning Traders in the world Good Luck to you all 👋 $Intelligent Group (INTJ.US)$ $Fractyl Health (GUTS.US)$ $Eyenovia (EYEN.US)$ $Zura Bio(ZURA.US$ $Haoxi Health Technology(HAO.US$ $Jin Medical International(ZJYL.US$
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg